INTRODUCTION N
Administrationn of heparin during cardiopulmonary bypass (CPB) surgery does not precludee coagulation activation, as evidenced by elevated concentrations of thrombinantithrombinn complexes (TAT) and prothrombin fragment F 1+2 in the systemic circulation. 1 
"
33 Previously, contact of blood with the extracorporeal circuit was thought to activatee the intrinsic pathway coagulation. 4 There is increasing evidence, however, for involvementt of tissue factor (TF)-factor VII-dependent coagulation activation, the extrinsicc pathway, especially in blood collecting in the pericardial cavity during CPB.
Comparedd to systemic blood, pericardial blood contains highly elevated concentrations of FF i+2, TAT and activated factor VII (Vila), reflecting its highly activated coagulation state. 1 ' 5 ' 66 To minimise blood loss, pericardial blood is returned into the patient, but this mayy activate systemic coagulation due to the presence of TF and factor Vila.
Factorr VII-dependent coagulation is initiated by TF, a transmembrane receptor forr factor VII/VIIa. Normally, cellular TF is not present within the blood but extravascular inn for example fibroblasts and smooth muscle cells. 7 ' 8 In pathological circumstances TF cann be expressed by monocytes and endothelial cells in vitro and possibly in vivo. Low concentrationss of non-cell bound TF are present in plasma, both in plasma from healthy individualss and at increased concentrations in for example malignant diseases, 9 angina pectoris 100 or disseminated intravascular coagulation (DIC) ." This non-cell bound TF is unlikelyy to initiate coagulation if truly 'soluble', because TF requires membrane associationn to become procoagulant.' 2 Recently,, concentrations of non-cell bound TF were shown to be elevated in pericardiall blood. 13 These authors hypothesized that part of the non-cell bound TF may be associatedd with the cell-derived microparticles which we reported previously to be present inn pericardial blood. 14 These microparticles initiated thrombin generation that was completelyy inhibited by tissue factor pathway inhibitor (TFPI) and strongly delayed in factorr VII-deficient plasma, and therefore likely to expose TF on their surface. More recently,, we showed that microparticles from peripheral blood of a patient with meningococcall disease and extensive diffuse intravascular coagulation exposed TF and initiatedd thrombin generation via the extrinsic pathway in vitro. 15 Inn the present study we investigated the extent of microparticle-association of the non-celll bound form of TF in pericardial blood from patients undergoing CPB and its capabilityy to support thrombin generation as compared to the fluid-phase form of non-cell boundd TF. We also investigated whether microparticle-associated TF may explain the hypercoagulationn found in the systemic circulation after return of the pericardial blood intoo the patient.
MATERIALL AND METHODS
Clinicall studies. This study was approved by the ethical committee of the Onze Lievee Vrouwe Gasthuis. Six patients undergoing elective coronary artery bypass grafting withh the use of CPB entered the study after their informed consent. Patients older than 85 yearss were excluded, and those with severe heart failure, renal or hepatic dysfunction, or a bleedingg diathesis. Patients did not receive coumarin derivatives, aspirin, dipyridamole or otherr nonsteroidal anti-inflammatory drugs within 5 days before the operation. Aprotinin orr other antifibrinolytics were not used during the operation. CPB procedure and anaesthesiaa were similar as described before, as was the treatment of the patients.
Heparinn (3 mg/kg) was given intravenously before cannulation of the aorta and repeated inn a dose of 50 mg whenever the activated clotting time (Hemocron; International Technidynee Corp., Edison, NJ) was shorter than 480 s.
Collectionn of blood samples. All systemic blood samples were drawn from the samee central venous line. Blood samples from the pericardial cavity were taken directly withh a 10 mL syringe. Sampling points of systemic blood (S) were after induction, before skinn incision (SI), 5 minutes after start of CPB (S2), 10 minutes before release of the aorticc crossclamp, at the start of the last distal anastomosis (S3), and before protamine administrationn (S4 (Greenwich,, CT). OT-2 (0.71 mg/mL), a monoclonal antibody (MoAb) inhibiting factor XIII activity, has been described earlier. 17 MoAbs directed against factor XI (clone XI-1)
andd factor VII (clones VII-1 and VII-15) activities were also from Sanquin. andd non-cell bound TF in samples S2-4 and P2-4 were corrected for hemodilution using theirr IgG content compared to that in S1.
Isolationn of microparticles.
Microparticles were isolated by differential centrifugationn as described previously. 18, 19 Briefly, the microparticles were pelleted from VII,, XI and XII were as described earlier. 19 We did not perform anti-TF studies, because previouslyy we observed no differences between anti-VII and anti-TF effects in the thrombinn generation assay. 15 ' 19 Thrombin activity, expressed as nmol/L, was calculated withh a reference curve of purified human a-thrombin (Sigma; St. Louis, MO, USA). 19 For quantitativee analysis, thrombin generation results were determined as area under the curve (AUC,, 0-15 minutes after addition of CaCl 2 ). Thrombin generation curves were not correctedd for the dilution factor of the pericardial blood, because the extent at which the AUCC is directly proportional to dilution, is not known. Microparticle-associatedd TF. To investigate whether non-cell bound TF was (partly)) microparticle-associated, plasma samples were subjected to high-speed centrifugationn and supernatant plasma as well as microparticle-containing pellets were assayedd for non cell-bound TF. In pericardial samples 21% (P2), 72% (P3) and 27% (P4)
off TF was microparticle-associated (figure 2). TF concentrations in systemic samples weree close to the detection limit and therefore too low to establish the microparticleassociatedd fraction of TF. Thrombinn generation by non-cell bound TF. Pericardial microparticles elicited twoo types of thrombin generation curves. Either curves similar to figure 3 A were obtained withh a thrombin peak after approximately 3 minutes and a delay in thrombin generation withh anti-factor VII. Alternatively, a gradually increasing thrombin generation was observedd up to about 10 minutes, which was also delayed by anti-factor VII ( figure 3B ).
Expressedd as AUC, systemic microparticles generated less thrombin ( figure 3C ) than pericardiall microparticles (figure 3D; P2 and P4 versus SI: p=0.009 and p=0.004, respectively).. Because of the differences in thrombin generation curves, the inhibitory effectss of anti-factor VII were both expressed as the extent of inhibition (figure 4 A) and as thee delay in onset (figure 4B) of thrombin generation. Anti-factor VII inhibited thrombin generationn initiated by pericardial microparticles (P2: 38%, P3: 55% and P4: 28%; all p=0.001)) or systemic microparticles from sampling point 4 (22%; p=0.003). Anti-factor VIII also strongly delayed thrombin generation induced by pericardial microparticles (4, 5 andd 3 minutes for microparticles from P2, P3 and P4, respectively, p<0.001), and approximatelyy 1.5 minutes with microparticles from S4. Anti-factor XI and anti-factor XII didd not substantially inhibit thrombin generation by pericardial microparticles (Table 1 ). Therefore,, the cellular origin of TF-exposing microparticles could not be established.
Totall plasma concentrations of non-cell bound TF. Because Triton X-100 improvedd the detection of the microparticle-associated form of non cell-bound TF by flow cytometry,, we hypothesized that part of the non-cell bound TF in plasma may also remain undetectedd by ELISA. In pericardial samples, total concentrations of non-cell bound TF increasedd 1.4-3.1 fold with Triton X-100 (Table 2 ), but not in systemic samples (data not shown).. This effect of Triton X-100 was most prominent in pericardial samples from collectionn points 2 and 4. As shown in Table 2 , the detection of fluid-phase TF also increasedd in the presence of Triton X-100. Thus, the concentrations of both forms of noncelll bound TF, which are the microparticle-associated form as well as the fluid phase form,, are underestimated in the absence of Triton X-100. 
DISCUSSION N
Inn systemic blood TF can be exposed on cells and be present in a non-cell bound form.
Thee present study shows that in pericardial plasma two forms of non-cell bound TF occur.
Onee form is microparticle-associated, whereas the other form is not. This latter form we calll fluid-phase TF, but it may be attached to albumin, lipoproteins, etc. So, in human bloodd TF can be present in a cell-bound form, a microparticle-associated form, and in a fluid-phasee form. To which extent non-cell bound TF in plasma from healthy human individualss is identical to non-cell bound TF in plasma from patients undergoing cardiac surgeryy remains to be determined.
Thee present study shows that only the microparticle-associated form of non-cell boundd TF generated thrombin. Previously, we showed that cell-derived microparticles in pericardiall blood originate from platelets (46%), erythrocytes (43%), and possibly granulocytess (10%). Since Triton X-100 impaired their identification, at present we can onlyy speculate which microparticles expose TF. Since TF has been found to be associated withh platelets, granulocytes, or microparticles derived therefrom, we hypothesize that at leastt part of the microparticle-associated form of non-cell bound TF may be exposed by suchh microparticles in pericardial blood. 21, 22 Our findings with Triton X-100 demonstrate thatt TF is detectable on some microparticles but not on all, and it is not clear whether thosee TF-positive microparticles -as demonstrated by flow cytometry-are indeed all capablee of thrombin generation. In fact, there is already some evidence suggesting that the procoagulantt activity of microparticle-exposed TF may be dependent on the cellular originn of the TF-exposing microparticles. Whereas we previously showed that microparticless of monocytic origin exposed coagulant TF in a patient with meningococcal septicc shock and severe disseminated intravascular coagulation, we more recently found increasedd numbers of especially platelet-derived microparticles exposing TF that were clearlyy not coagulant.
15
' 27 Thus, at present, we cannot exclude that some differences in cellularr origin of TF-exposing microparticles between plasma samples may affect the thrombinn generation capacity. In an attempt to characterize the microparticle-associated form(s)) of TF, we applied pericardial and systemic microparticles to Western blot.
Stainingg by anti-TF only revealed a weak band of approximately 45 kDa in the pericardial microparticlee fraction (data not shown), suggesting that at least part of TF present in these sampless is of the full-length form. From these data, however, we cannot exclude that 'microparticle-associatedd TF' still may contain several forms of both active and/or inactivee TF.
Inn the pericardial blood samples with the highest concentration of non-cell bound TF,, TAT, and F 1+2 , which is at sample point P3, up to 77% of the non-cell bound TF was inn the microparticle-associated form. The other pericardial blood samples (P2 and P4), Thee factor-VII dependent coagulation pathway was involved in the thrombin generationn of the microparticle-associated form of TF. This was shown by inhibition of thrombinn generation by anti-factor VII, both expressed as the AUC and the delay in onset off thrombin generation. In most institutes for cardiosurgery, pericardial wound blood is returnedd into the systemic circulation during and especially at the end of the CPB proceduree to reduce blood loss. We observed systemic coagulation activation in blood sampless collected at the end of the bypass (S4), despite heparinization. Moreover, antifactorr VII inhibited thrombin generation only when initiated by systemic microparticles collectedd at the end of bypass. Therefore, we hypothesize that pericardial microparticles afterr their return into the circulation are responsible for the systemic coagulation activation. .
Itt is tempting to speculate that the transfusion of the pericardial cavity blood, and thuss of high numbers of procoagulant microparticles with the active TF on their surface, mayy contribute to the post-operative thrombotic complications such as graft occlusion, silentt deep vein thrombosis and adverse neurological events in patients undergoing cardiacc surgery assisted by CPB. 23 " 25 Bonderman et al. already showed in a porcine model thatt intracoronary injection of relipidated human TF induces coronary no-reflow by a thrombus. 26 6 Inn summary, our present findings show that non-cell bound TF may occur in a microparticle-associatedd and in a fluid-phase form in human plasma. The microparticleassociatedd form was capable of factor VII-mediated thrombin. In contrast, the fluid-phase formm did not initiate thrombin generation. The contribution of pericardial blood to systemicc coagulation activation may explain the coagulation activation at the end of the CPB.. Furthermore, we hypothesize that in other clinical conditions, 9 " 11 in which elevated concentrationss of non-cell bound TF antigen in plasma were paralleled by an increased riskrisk for thromboembolic events, the microparticle-associated form of non-cell bound TF is likelyy to contribute to systemic coagulation activation.
